利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.061 秒)

    Chordin-like homologs
    1.
    发明申请
    Chordin-like homologs 审中-公开
    Chordin样同系物

    公开(公告)号：US20050118615A1

    公开(公告)日：2005-06-02

    申请号：US10913447

    申请日：2004-08-09

    申请人： Anat Oren ,  Galit Rotman ,  Amir Toporoik ,  Sharon Biton ,  Kinneret Savitsky ,  Jeanne Bernstein

    发明人： Anat Oren ,  Galit Rotman ,  Amir Toporoik ,  Sharon Biton ,  Kinneret Savitsky ,  Jeanne Bernstein

    IPC分类号： A61K38/00 ,  C07K14/475 ,  C12Q1/68 ,  A61K38/18 ,  A61K48/00 ,  G01N33/53

    CPC分类号： C07K14/475 ,  A61K38/00

    摘要： The present invention concerns several splice variants of a Chordin like homologues (CHL2) and depicts their nucleic acid and amino acid sequences, vectors and host cells containing said nucleic acid sequences and antibodies reactive with the amino acid sequences. The invention also concerns pharmaceutical compositions for the treatment of a plurality of diseases, comprising nucleic acid sequences, amino acid sequences, expression vectors and antibodies. The invention also concerns methods for detecting the above nucleic acid or amino acid sequences or antibodies in a biological sample.

    摘要翻译： 本发明涉及Chordin样同系物（CHL2）的若干剪接变体，并描述了其核酸和氨基酸序列，含有所述核酸序列的载体和宿主细胞和与氨基酸序列反应的抗体。 本发明还涉及用于治疗多种疾病的药物组合物，包括核酸序列，氨基酸序列，表达载体和抗体。 本发明还涉及用于检测生物样品中的上述核酸或氨基酸序列或抗体的方法。

    Novel CD40 variants
    6.
    发明申请
    Novel CD40 variants 审中-公开
    新型CD40变体

    公开(公告)号：US20060287229A1

    公开(公告)日：2006-12-21

    申请号：US11172493

    申请日：2005-06-30

    申请人： Dani Eshel ,  Galit Rotman ,  Kinneret Savitsky ,  Amir Toporik ,  Rami Khosravi ,  Aviva Chen ,  Yona Bismuth

    发明人： Dani Eshel ,  Galit Rotman ,  Kinneret Savitsky ,  Amir Toporik ,  Rami Khosravi ,  Aviva Chen ,  Yona Bismuth

    IPC分类号： A61K38/17

    CPC分类号： A61K38/177

    摘要： The invention concerns CD40 skipping 5 nucleic acid sequences and amino acid sequences obtained by alternative splicing of CD40, pharmaceutical compositions comprising said sequences and methods for treatment of a disease, wherein a beneficial therapeutic effect is achieved by the up regulation of the CD40-R-CD40-L interaction. An antibody capable of selectively binding to the amino acid of CD40 skipping 5 and pharmaceutical composition comprising the above antibody and methods for detecting the presence of exon 5 skipping expression in a sample are also within the scope of the invention.

    摘要翻译： 本发明涉及跳过5个核酸序列和通过CD40的选择性剪接获得的氨基酸序列，包含所述序列的药物组合物和治疗疾病的方法的CD40，其中有益的治疗效果通过上调CD40-R- CD40-L相互作用。 能够选择性地结合CD40跳跃5的氨基酸的抗体和包含上述抗体的药物组合物和用于检测样品中外显子5跳跃表达的存在的方法也在本发明的范围内。